Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Euthymics Bioscience Inc.

euthymics.com

Latest From Euthymics Bioscience Inc.

Deal Watch: Otsuka’s Neurovance Buy Adds ADHD Candidate To CNS Pipeline

Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.

Deals M & A

Start-Up Previews (03/2011)

A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Antidepressants: Emerging From Their Funk?," includes profiles of Euthymics Bioscience, Naurex and PharmaNeuroBoost. Plus these Start-Ups Across Health Care: Edge Therapeutics, Ensemble Therapeutics, Magnetecs, Mederi Therapeutics and Surefire Medical.

Antidepressants: Emerging From Their Funk?

Forest’s acquisition of Clinical Data to get its just-approved antidepressant signals continuing strong demand. But better, and much needed, treatments remain elusive. We profile four emerging antidepressant drug developers in this issue: Euthymics Biosciences, Naurex and PharmaNeuroBoost.
BioPharmaceutical

Euthymics Bioscience Inc.

There’s nothing new to the notion of combining CNS modulators to create synergistic formulations for treating depression, but tuning the balance has been difficult. Euthymics Bioscience Inc. thinks it has found the right mix. The company’s formula, now in midstage clinical testing, combines serotonin, norepinephrine and dopamine modulators in a way that results in a ratio of 1:2:8. The company plans to test its candidate against paroxetine to show improvement over a generic standard of care. If it succeeds, it could move to the front of the second line of antidepressant agents.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Euthymics Bioscience Inc.
  • Senior Management
  • Anthony A McKinney, Pres. & CEO
    Thomas A Shea, CFO
    Franklin P Bymaster, CSO
    Pierre Tran, MD, CMO
  • Contact Info
  • Euthymics Bioscience Inc.
    Phone: (617) 758-0300
    43 Thordike St.
    Ste S1-3
    Cambridge, MA 02141
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register